ARTICLE | Product Development
Revamping Acadia
Can the long-time neuropsych company couple its new management with a pivot to rare disease to climb back up the market cap tiers?
August 7, 2025 1:05 AM UTC
With new leadership, rising sales and an expanding pipeline, 32-year-old Acadia Pharmaceuticals aims to lay the groundwork for a comeback. Unlike many companies struggling right now, Acadia’s problem isn’t cash. Rather, it’s how to both convince investors it’s on the right path, and deliver data based on its revamped strategy.
After a series of missed opportunities that erased more than half its market value, Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is charting a new course via a pivot to rare diseases, with a new approach to precision decision-making rooted in its reinvigorated commercial and R&D strategy...